El futuro del paradigma de tratamiento del CPNM. ¿Hacia dónde vamos?

En este 3r y último bloque, el Dr. Bosch junto al Dr. Trigo y al Dr. Vázquez, cierran con broche de oro esta serie de conversaciones sobre los avances presentados en ESMO, dando su opinión sobre la relevancia y hacia dónde nos pueden conducir los últimos datos del EMPOWER-Lung 01, el update del estudio ADAURA, el estudio INCREASE, los datos presentados del CodeBreak 200...

Bahce I, et al. Abstract 950O presented at ESMO 2022. Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable lung cancer: The INCREASE trial

Tsuboi M, et al. LBA47 presented at ESMO 2022. Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA

Ozguroglu M, et al. LBA54 presented at ESMO 2022. Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): The EMPOWER-Lung 1 trial

Johnson ML, et al. LBA10 presented at ESMO 2022. Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study. 

Ming Lee S, et al. LBA11 presented at ESMO 2022. IPSOS: Results from a Phase 3 study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen